´Ý±â
TaKaRa
Á¦Ç°¸í/Á¦Ç°ÄÚµå
Å°¿öµå°Ë»ö
°Ë»ö
´Ý±â
  • °í°´Áö¿ø 
  • ¾÷¹«¾È³»¦¢Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢02-2081-2510
  • Email     ¦¢support@takara.co.kr
  • ´ëÀüÁö»ç 
  • ¾÷¹«¾È³»¦¢´ëÀü/ÃæûÁö¿ª ÁÖ¹®, Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢042-828-6525
  • Email     ¦¢tkbd@takara.co.kr
  • ¾÷¹«½Ã°£¾È³»
  • [ Æò¡¡¡¡ÀÏ ] 09 : 00 ~ 18 : 00 ¦¢ [ Á¡½É½Ã°£ ] 12 : 00 ~ 13 : 00
  • Å䡤ÀÏ¿äÀÏ, °øÈÞÀÏÀº ÈÞ¹«ÀÔ´Ï´Ù.
Home > Á¤º¸ÀÚ·á

    ¿Â¶óÀÎÅø

-
A Complete Culture System for Human Induced Pluripotent Stem Cells
Solutions for maintaining human induced pluripotent stem cell lines-feeder-free, defined conditions and single-cell enzymatic passaging provide unparalleled experimental flexibility DEF-CS culture system as a complete solution to purity issues-promotes homogeneous undifferentiated cells with virtually no spontaneous differentiation Description of the step-by-step protocol-includes passaging, guidelines for cell line transfer from other systems, and applications
-
Make Your Own Hepatocytes from iPS Cells
Description of a standardized hepatocyte differentiation protocol-validated on 25 different hiPS cell lines, without the need for optimization
Development of panels of hiPSC-derived hepatocytes with diverse genetic backgrounds-ideal for drug metabolism and safety studies
Applications for disease modeling and safety toxicology-start with any patient-specific hiPS cell lines
-

[2016 ¿Â¶óÀμ¼¹Ì³ª] Human iPS cellsÀÇ È¿°úÀûÀÎ È®´ë ¹è¾çÀ» À§ÇÑ Cellartis¢ç DEF-CS Culture System
  • Human induced pluripotent stem cell lines À¯Áö ¹è¾ç
    feeder-free, defined conditionÀ¸·Î single-cell enzymatic passaging °¡´É
  • ¹ÌºÐÈ­»óÅ À¯Áö¿¡ Ź¿ùÇÑ DEF-CS ¹è¾ç ½Ã½ºÅÛ
    ºñÀǵµÀû ºÐÈ­¾øÀÌ µ¿ÁúÀÇ ¹ÌºÐÈ­ ¼¼Æ÷ »óÅ À¯Áö
  • Genome editing ÈÄ ¶Ù¾î³­ single cell cloning È¿À²
    hiPS cell colonyÀÇ °­·ÂÇÑ proliferation°ú single cell cloning ÈÄ pluripotency À¯Áö

-
[2016 ¿Â¶óÀμ¼¹Ì³ª] Human iPS cell À¯·¡ Hepatocyte - µ¶¼º ¿¬±¸¸¦ À§ÇÑ Çõ½ÅÀûÀÎ Tool
±âÁ¸ µ¶¼º Å×½ºÆ®¿¡ ÀÌ¿ëµÇ´Â primary hepatocytes, hepatoma cell line, animal model µî°ú °°Àº ½ÇÇè ¸ðµ¨¿¡ ´ëÇÑ ´ë¾ÈÀ¸·Î ¶°¿À¸£´Â human iPS cell À¯·¡ÀÇ hepatocyte¿¡ °üÇÏ¿© Ç¥ÁØ ÇÁ·ÎÅäÄÝÀ» ÀÌ¿ëÇÑ ºÐÈ­ °úÁ¤°ú Ư¼º °ËÁõ ¹× Àû¿ë ¿¹¸¦ ¼Ò°³ÇÏ°íÀÚ ÇÑ´Ù.

* Ç¥ÁØÈ­ÇÑ hepatocyte ºÐÈ­ ÇÁ·ÎÅäÄÝ ¼³¸í
   - 25°³ÀÇ hiPS cell lines¿¡¼­ º°µµÀÇ ÃÖÀûÈ­ °úÁ¤ ¾øÀÌ ºÐÈ­ °ËÁõ
* ´Ù¾çÇÑ genetic background¸¦ °¡Áø hiPSC-derived hepatocyte ÆгÎ
   - ¾à¹° ´ë»ç ¿¬±¸³ª ¾ÈÀü¼º ¿¬±¸¿¡ ÀÌ»óÀû
* Áúº´ ¸ðµ¨À̳ª µ¶¼º Å×½ºÆ® Àû¿ë¿¡ À¯¿ë
   - ȯÀÚ Æ¯ÀÌÀû hiPS cell linesÀ¸·Î ½ÃÀÛÇϰųª ±âÁ¸ ¸¸µé¾îÁø hiPS-HEP cells·Î Àû¿ë °¡´É
-

[2017 ¿Â¶óÀμ¼¹Ì³ª] ½Å¾à°³¹ßÀ» À§ÇÑ °³¼±µÈ Àΰ£ °£¼¼Æ÷ ¸ðµ¨
º» ¼¼¹Ì³ª¿¡¼­´Â ±âÁ¸ÀÇ primary hepatocyte model¿¡¼­ ºÒ°¡´É Çß´ø Hepatitis virus infection, chronic toxicity study¸¦ À§ÇØ 4ÁÖ°£ Àå±â¹è¾çÀÌ °¡´ÉÇÑ human primary hepatocyte medium. ´ëÇü assay ¹× ½Å¾à screeningÀ» À§ÇØ ´ë·®»ý»êÀÌ °¡´ÉÇÑ human iPS derived hepatocyteµî È¿À²ÀûÀÎ ½Å¾à°³¹ßÀ» À§ÇÑ °³¼±µÈ Àΰ£ °£¼¼Æ÷ ¸ðµ¨À» ¼Ò°³ÇÕ´Ï´Ù

-

[2017 ¿Â¶óÀμ¼¹Ì³ª] 2017³â »ýÈ­ÇÐ ºÐÀÚ»ý¹°ÇÐȸ ¾ÞÄÝ ¼¼¹Ì³ª: Gene Editing of Human iPS cells
ÇÐȸ¿¡ Âü¼®ÇÏÁö ¸øÇϽŠ°í°´ ºÐµéÀÇ ¸¹Àº °ü½É¿¡ µû¶ó µ¿Àϳ»¿ëÀ¸·Î ÁøÇàµÈ Çѱ¹¾î ¹öÀü ¾ÞÄÝ ¼¼¹Ì³ª ÀÔ´Ï´Ù. CRISPR/Cas9À» »ç¿ëÇÑ human iPS cell À¯ÀüÀÚ ±³Á¤°ú DEF-CS¢â 500 culture systemÀ» »ç¿ëÇÑ human iPS cell clonal line Á¦ÀÛ°úÁ¤À» ¼Ò°³ÇÕ´Ï´Ù

  • Guide-it¢â Recombinant Cas9
    Cas9-sgRNA RNP complex »ç¿ëÀ¸·Î gene editingÀÇ ¾ÈÁ¤¼º°ú ƯÀ̼º Çâ»ó
  • Cellartis¢ç DEF-CS¢â 500
    Monolayer culture·Î °íÈ¿À²ÀÇ gene editing °¡´É
    °­·ÂÇÑ human iPS single cell cloning ´É·Â
-